<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18287">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874210</url>
  </required_header>
  <id_info>
    <org_study_id>S51367</org_study_id>
    <nct_id>NCT01874210</nct_id>
  </id_info>
  <brief_title>Study on Colonic Fermentation in Chronic Kidney Disease Patients</brief_title>
  <official_title>Study on Colonic Fermentation in Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease is associated with the accumulation of various metabolites, i.e.,
      uremic retention solutes. Evidence is mounting that the colonic microbiome contributes
      substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are
      among the most extensively studied gut microbial metabolites, and are associated with
      cardiovascular disease, chronic kidney disease progression and overall mortality. Indirect
      findings suggest that chronic kidney disease influences the colonic microbial metabolism
      with higher p-cresyl sulfate urinary excretion rates at more advanced renal disease.
      Therefore, this study aims to elucidate the influence of renal dysfunction on microbial
      metabolism and to test the hypothesis that chronic kidney disease patients carry a different
      fecal metabolite profile.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>difference in fecal metabolite profile (Chronic kidney disease vs. control)</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>difference in fecal metabolite profile between chronic kidney disease patients and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference in fecal metabolite profile depending on dialysis modality</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>difference in fecal metabolite profile between hemodialysis patients and peritoneal patients</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Hemodialysis</arm_group_label>
    <description>Hemodialysis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <description>Peritoneal dialysis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Household contacts on the same diet
Healthy unrelated controls</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal sample, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with renal replacement therapy, i.e. hemo- or peritoneal dialysis for
        more than 3 months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 95 years

          -  Treatment with renal replacement therapy, i.e. hemo- or peritoneal dialysis for more
             than 3 months

          -  Written informed consent

        Exclusion Criteria:

          -  History of organic gastro-intestinal disease (e.g., inflammatory bowel disease,
             malignancy)

          -  History of colonic surgery

          -  Recipient of a renal or other solid organ transplant

          -  Use of pre-/pro-/syn- or antibiotics in preceding 4 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Poesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Björn Meijers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristin Verbeke, Pharm PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter Evenepoel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruben Poesen, MD</last_name>
    <phone>+3216 33 00 10</phone>
    <email>ruben.poesen@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Poesen, MD</last_name>
      <phone>+3216 33 00 10</phone>
      <email>ruben.poesen@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
